JNJ-2113 is under clinical development by Johnson & Johnson and currently in Phase III for Psoriatic Arthritis.

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis (PsA ... disease-modifying antirheumatic ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

INR:2395. best online crypto casino btc7777 The department director must agree! The document on strict management of ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

INR:8332. rummy type Amgen acquires Celgene's new psoriatic arthritis drug Otezla for $13.4 billion Alphamab Oncology's PD-L1/CTLA-4 dual antibody KN046 received appro ...

INR:0819. ludo dice png AbbVie's JAK inhibitor approved for psoriatic arthritis and ankylosing spondylitis Vitrakvi, the first "broad-spectrum" anticancer drug that ...

FDA confirms end of Zepbound shortage, but announces new shortages for other medications, including Humira biosimilar and painkillers. Details here.